Titan Pharmaceuticals, Inc.

TTNP

US8883147055

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-21 pm EDT			5-day change	1st Jan Change
6.35 ^USD	-1.55%		-3.23%	-23.03%

Apr. 01	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 26	Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule	MT

Titan Pharmaceuticals, Inc. Announces Executive Changes

October 15, 2020 at 08:00 am EDT

Titan Pharmaceuticals, Inc. announced that Titan's President, Sunil Bhonsle, has expressed his desire to retire. Accordingly, the current Executive Chairman, Marc Rubin, M.D., will assume the position of Chairman, and its current Executive Vice President and Chief Scientific Officer, Kate Beebe DeVarney, Ph.D., will be appointed President and Chief Operating Officer.

Latest news about Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule	Jan. 26	MT
Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024	Jan. 18	CI
Titan Pharmaceuticals to Implement 1-for-20 Reverse Stock Split	Dec. 29	MT
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Titan Pharmaceuticals, Inc. Announces Board Changes	23-10-16	CI
Titan Pharmaceuticals Appoints New Chairman of the Board	23-10-16	MT
Titan Pharmaceuticals, Inc. Announces Board Resignations	23-09-19	CI
Titan Pharmaceuticals, Inc. announced that it expects to receive $9.5 million in funding from Sire Group Ltd	23-09-12	CI
Fedson, Inc. completed the acquisition of Certain ProNeura Assets of Titan Pharmaceuticals, Inc..	23-08-31	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. for $52 million.	23-07-26	CI
Titan Pharmaceuticals, Inc. Announces Board Changes	23-07-07	CI
Insider Sell: Titan Pharmaceuticals	23-06-23	MT
Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Titan Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Sector Update: Health Care Stocks Sink on Thursday	22-12-15	MT
Sector Update: Health Care	22-12-15	MT
Titan Pharmaceuticals Signs Letter of Intent for Reverse Merger; Shares Drop	22-12-15	MT
Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022	22-12-15	CI
Titan Pharmaceuticals, Ocular Therapeutix Sign Licensing Agreement on Ophthalmic Patent Applications in US	22-12-12	MT
Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc	22-12-12	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Declaration of Voting Results by Titan Pharmaceuticals, Inc	22-08-16	CI

Chart Titan Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Sector

Pharmaceuticals

Calendar

2024-11-10 - Q3 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
TITAN PHARMACEUTICALS, INC.	-23.03%	5.9M
ELI LILLY AND COMPANY	+37.78%	705B
NOVO NORDISK A/S	+32.82%	583B
JOHNSON & JOHNSON	-3.51%	364B
MERCK & CO., INC.	+19.94%	332B
ABBVIE INC.	+5.14%	291B
ASTRAZENECA PLC	+16.64%	238B
ROCHE HOLDING AG	-4.13%	210B
NOVARTIS AG	+10.63%	209B
AMGEN INC.	+9.32%	169B

Other Pharmaceuticals